Table 3.

Univariate analysis: Influence on TTP (second-line)

Factor	Median TTP (months)	95% CI	SE*	p =
Age > 65 years	6 vs. 7	0.00-12.79	3.36	n.s.
		5.64-8.36	0.7
Age < 35 years	3 vs. 7	0.23-5.77	1.41	0.026
		5.67-8.33	0.68
Stage 4 at diagnosis	6 vs. 7	5.52-8.48	0.76	n.s.
		0.39-11.61	2.86
Grading (1,2 versus 3)	6 vs. 7	2.98-9.03	1.54	n.s.
		5.6-8.41	0.72
Histologic type (ductal versus lobular)	6 vs. 9	4.86-7.14	0.58	n.s.
		0.71-17.29	4.23
Positive hormone receptor status	6 vs. 7	4.64-7.36	0.7	n.s.
		5.14-8.86	0.95
Time to recurrence < 12 months	6 vs. 7	3.41-8.59	1.32	n.s.
		5.61-8.39	0.71
Visceral metastases	7 vs. 6	5.76-8.25	0.64	n.s.
		0.00-12.53	3.33
Number of metastatic sites (1 versus 2)	14 vs. 6	9.56-18.44	2.26	0.013
		5.02-6.98	0.5
Number of metastatic sites (2 versus > 2)	8 vs. 6	5.58-10.42	1.23	0.003
		5.09-6.91	0.47
Trastuzumab from first-line palliative treatment	7 vs. 6	5.62-8.38	0.71	n.s.
		4.65-7.35	0.69
Response to first-line trastuzumab-based therapy	7 vs. 6	5.25-8.75	0.89	n.s.
		3.77-8.23	1.14
New metastatic sites at progression upon first-line trastuzumab-based therapy	7 vs. 6	4.81-9.19	1.12	n.s.
		5.12-6.88	0.45

* SE: Standard error